NCT03190083 is a NA clinical trial of 2-dimensional mammogram in Breast Cancer, sponsored by Case Comprehensive Cancer Center.

Who is sponsoring NCT03190083?

NCT03190083 is sponsored by Case Comprehensive Cancer Center.

What drugs are being tested in NCT03190083?

Interventions in NCT03190083: 2-dimensional mammogram, digital breast tomosynthesis (DBT).

What condition does NCT03190083 study?

NCT03190083 studies Breast Cancer.

Is NCT03190083 still recruiting?

NCT03190083 is currently completed. Last updated 27 June 2022.

Are results published for NCT03190083?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-06-27 · How we verify

NCT03190083

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Digital Breast Tomosynthesis + Standard 2- Dimensional Mammography in Breast Cancer

Completed NA Results posted Last updated 27 June 2022

What this trial tests

NA trial testing 2-dimensional mammogram in Breast Cancer in 16 participants. Completed in 13 June 2018.

Timeline

1 July 2017

Primary endpoint
13 June 2018

13 June 2018

Quick facts

Lead sponsor	Case Comprehensive Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	16
Start date	1 July 2017
Primary completion	13 June 2018
Estimated completion	13 June 2018
Sites	1 location across United States

Drugs / interventions tested

2-dimensional mammogram
digital breast tomosynthesis (DBT)

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Case Comprehensive Cancer Center — full company profile →

Who can join

Adults 25 to 85, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants for Which DBT Altered Surgical Plan Primary · At completion of 3-Dimensional mammogram (1 day)

Only positive findings, like an additional site of cancer or atypical pathology like Atypical ductal/ lobular hyperplasia, papilloma, DCIS/LCIS (findings requiring surgical intervention), will be taken into account when estimating the frequency of changes to surgical management

Group	Value	95% CI
3-dimensional Tomosynthesis Mammogram	0

Sponsor's own description

The purpose of this study is to determine if a 3-dimensional mammogram (DBT) may provide additional information to evaluate the extent of disease and additional findings that would aid in staging a new breast cancer patient. This would impact surgical planning and improve patient outcomes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Recent Advancements of Nanomedicine in Breast Cancer Surgery.
Meng X, Wang X, Zhang Z, Song L, et al · · 2024 · cited 5× · PMID 39759962 · DOI 10.2147/ijn.s494364

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Case Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) · NA · not yet recruiting
NCT07167056 — Artificial Intelligence-Powered Support For Quality Of Life Improvement In Participants With Cancer · NA · recruiting
NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
NCT07044362 — Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03190083 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Case Comprehensive Cancer Center
Last refreshed: 27 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03190083.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing